FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

Nusinersen is currently commercialized under the brand name SPINRAZA in over 71 countries at the label-approved dose of 12 mg. “Continued progress to improve upon the remarkable initial ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

The STRENGTH study found OAV101 IT stabilized motor function in patients who had discontinued Spinraza or Evrysdi ... who had discontinued treatment with nusinersen or risdiplam.

Additionally, in the phase IIIb STRENGTH study, treatment with OAV101 IT demonstrated stabilization of motor function over 52 weeks of follow-up in patients who had previously discontinued treatment ...

The company confirmed today that regulators in the US and Europe have started reviews of a new regimen based on two 50mg doses of Spinraza (nusinersen) given 14 days apart, followed by a higher ...

Treatment with Spinraza (nusinersen) can help stabilize or improve motor function in adults with SMA, according to a new ...